Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
LH
$251.81
$-2.86
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Next Earnings
2026-01-11
Beta
0.97
Average Volume
796543
Market Cap
20875049000
Last Dividend
2.88
CIK
0000920148
ISIN
US5049221055
CUSIP
504922105
CEO
Adam H. Schechter
Sector
Healthcare
Industry
Medical - Equipment & Services
Full Time Employees
60900
IPO Date
1990-03-29
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Labcorp Holdings Inc. $LH Shares Sold by Cerity Partners LLC | Cerity Partners LLC decreased its position in shares of Labcorp Holdings Inc. (NYSE: LH) by 5.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,384 shares of the medical research company's stock after selling 4,085 shares during the quarter. Cerity | Defense World | 2026-01-10 03:40:56 |
| Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs | SAN JOSE, Calif.--(BUSINESS WIRE)--Today, Visby Medical announced two new relationships that will expand national access to the Visby Women's Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby's integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomonia. | Business Wire | 2026-01-08 09:00:00 |
| NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp | TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. | PRNewsWire | 2026-01-08 08:30:00 |
| Should Labcorp Stock Stay in Your Portfolio Right Now? | LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks. | Zacks Investment Research | 2026-01-06 09:15:36 |
| Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference | BURLINGTON, N.C., Dec. 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 44th Annual J.P. | PRNewsWire | 2025-12-30 16:15:00 |
| Labcorp Holdings Inc. (NYSE:LH) Receives Consensus Rating of “Moderate Buy” from Analysts | Shares of Labcorp Holdings Inc. (NYSE: LH - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the fifteen analysts that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12 month price objective | Defense World | 2025-12-30 01:48:52 |
| Here's Why Labcorp Holdings (LH) is a Strong Value Stock | Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. | Zacks Investment Research | 2025-12-22 10:41:24 |
| HOLX vs. LH: Which MedTech Stock Is the Stronger Investment Now? | Labcorp's strategic partnerships, specialty test growth and more attractive valuation tilt the balance as it emerges stronger than Hologic right now. | Zacks Investment Research | 2025-12-22 09:01:15 |
| Osaic Holdings Inc. Raises Stock Holdings in Labcorp Holdings Inc. $LH | Osaic Holdings Inc. increased its stake in shares of Labcorp Holdings Inc. (NYSE: LH) by 13.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,620 shares of the medical research company's stock after purchasing an additional 4,690 | Defense World | 2025-12-21 05:18:58 |
| Assenagon Asset Management S.A. Trims Position in Labcorp Holdings Inc. $LH | Assenagon Asset Management S.A. decreased its holdings in shares of Labcorp Holdings Inc. (NYSE: LH) by 69.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,212 shares of the medical research company's stock after selling 83,746 shares during the quarter. Assenagon Asset | Defense World | 2025-12-21 03:46:43 |
| Labcorp Holdings Inc. $LH Holdings Lowered by Bartlett & CO. Wealth Management LLC | Bartlett and CO. Wealth Management LLC cut its stake in Labcorp Holdings Inc. (NYSE: LH) by 1.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 208,210 shares of the medical research company's stock after selling 2,595 shares during | Defense World | 2025-12-20 03:33:09 |
| Is the Options Market Predicting a Spike in Labcorp Holdings Stock? | Investors need to pay close attention to LH stock based on the movements in the options market lately. | Zacks Investment Research | 2025-12-15 10:01:52 |
| Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks | ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor's nationwide expansion and broaden patient access to its immunotherapy-response diagnostics. Ascension Ventures, the strategic investment arm of 13 leading U.S. health systems across 22 states, representing more than $100. | Business Wire | 2025-12-15 10:00:00 |
| Cerity Partners LLC Has $21.64 Million Stock Holdings in Labcorp Holdings Inc. $LH | Cerity Partners LLC decreased its position in Labcorp Holdings Inc. (NYSE: LH) by 2.8% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 82,469 shares of the medical research company's stock after selling 2,348 shares during the period. Cerity | Defense World | 2025-12-10 04:35:13 |
| Ariel Investments LLC Sells 2,865 Shares of Labcorp Holdings Inc. $LH | Ariel Investments LLC lessened its position in Labcorp Holdings Inc. (NYSE: LH) by 0.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 365,398 shares of the medical research company's stock after selling 2,865 shares during the quarter. Ariel Investments | Defense World | 2025-12-10 03:31:12 |
| Rep. April McClain Delaney Buys Brown & Brown, Inc. (NYSE:BRO) Stock | Representative April McClain Delaney (D-Maryland) recently bought shares of Brown and Brown, Inc. (NYSE: BRO). In a filing disclosed on December 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Brown and Brown stock on November 20th. Representative April McClain Delaney also recently made the following trade(s): Sold $1,001 - $15,000 in | Defense World | 2025-12-10 02:04:55 |
| Rep. April McClain Delaney Purchases Shares of Labcorp Holdings Inc. (NYSE:LH) | Representative April McClain Delaney (D-Maryland) recently bought shares of Labcorp Holdings Inc. (NYSE: LH). In a filing disclosed on December 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Labcorp stock on November 17th. Representative April McClain Delaney also recently made the following trade(s): Purchased $1,001 - $15,000 in shares of Brown | Defense World | 2025-12-10 02:04:54 |
| Markel Group (NYSE:MKL) Shares Acquired Rep. April McClain Delaney | Representative April McClain Delaney (D-Maryland) recently bought shares of Markel Group Inc. (NYSE: MKL). In a filing disclosed on December 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Markel Group stock on November 3rd. Representative April McClain Delaney also recently made the following trade(s): Purchased $1,001 - $15,000 in shares of | Defense World | 2025-12-10 02:04:50 |
| EMCOR Group (NYSE:EME) Stock Unloaded Rep. April McClain Delaney | Representative April McClain Delaney (D-Maryland) recently sold shares of EMCOR Group, Inc. (NYSE: EME). In a filing disclosed on December 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in EMCOR Group stock on November 17th. Representative April McClain Delaney also recently made the following trade(s): Purchased $1,001 - $15,000 in shares of | Defense World | 2025-12-10 02:04:48 |
| Labcorp Holdings Inc. $LH Shares Sold by Brown Advisory Inc. | Brown Advisory Inc. lessened its stake in shares of Labcorp Holdings Inc. (NYSE: LH) by 10.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,363 shares of the medical research company's stock after selling 7,248 shares during the quarter. Brown Advisory | Defense World | 2025-12-08 04:54:58 |
| Labcorp Holdings Inc. (NYSE:LH) Receives Average Recommendation of “Moderate Buy” from Analysts | Shares of Labcorp Holdings Inc. (NYSE: LH - Get Free Report) have received a consensus rating of "Moderate Buy" from the sixteen research firms that are currently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average | Defense World | 2025-12-05 02:16:47 |
| Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp | FRANKLIN, Tenn. & BURLINGTON, N.C.--(BUSINESS WIRE)--Community Health Systems, Inc. (the “Company”) (NYSE: CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has completed the sale of select assets of the ambulatory outreach laboratory services of CHS-affiliated health systems in 13 states, including certain patient service centers and in-office phlebotomy locations, to Labcorp (NYSE: LH) for approximately $194 million cash, before certain transaction expenses. | Business Wire | 2025-12-02 16:15:00 |
| Should You Continue to Hold LH Stock in Your Portfolio? | Labcorp expands in specialty testing and ramps up acquisitions, but macro pressures and currency headwinds complicate its growth outlook. | Zacks Investment Research | 2025-12-02 08:55:18 |
| Boston Family Office LLC Acquires New Holdings in Labcorp Holdings Inc. $LH | Boston Family Office LLC bought a new position in Labcorp Holdings Inc. (NYSE: LH) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 850 shares of the medical research company's stock, valued at approximately $223,000. Other hedge funds also recently modified | Defense World | 2025-12-02 05:12:59 |
| Labcorp Holdings Inc. $LH Position Cut by Brandes Investment Partners LP | Brandes Investment Partners LP reduced its holdings in Labcorp Holdings Inc. (NYSE: LH) by 57.6% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 205,647 shares of the medical research company's stock after selling 279,196 shares during the quarter. | Defense World | 2025-12-02 04:36:48 |
| Advisors Asset Management Inc. Buys 770 Shares of Labcorp Holdings Inc. $LH | Advisors Asset Management Inc. grew its stake in Labcorp Holdings Inc. (NYSE: LH) by 19.4% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,734 shares of the medical research company's stock after acquiring an additional 770 shares during the quarter. Advisors | Defense World | 2025-12-01 03:14:56 |
| Labcorp (LH) Up 8.1% Since Last Earnings Report: Can It Continue? | Labcorp (LH) reported earnings 30 days ago. What's next for the stock? | Zacks Investment Research | 2025-11-27 12:31:07 |
| Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term | Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. | Zacks Investment Research | 2025-11-25 10:41:36 |
| Labcorp Appoints Victor Bulto to Board of Directors | Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. | PRNewsWire | 2025-11-24 08:30:00 |
| Cetera Investment Advisers Lowers Stock Position in Labcorp Holdings Inc. $LH | Cetera Investment Advisers lessened its holdings in Labcorp Holdings Inc. (NYSE: LH) by 1.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,648 shares of the medical research company's stock after selling 268 shares during the period. | Defense World | 2025-11-24 04:38:54 |
| LH Shares Gain Following Publication of New Plasma Detect MRD Data | Labcorp shares edge higher as new studies spotlight Plasma Detect's role in tracking MRD and improving post-surgery cancer detection. | Zacks Investment Research | 2025-11-21 09:16:10 |
| Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research | Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research BURLINGTON, N.C. , Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two recent peer-reviewed publications – Nature Medicine and Clinical Cancer Research. | PRNewsWire | 2025-11-19 07:04:00 |
| Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research | DURHAM, N.C. and SEOUL, South Korea , Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care. | PRNewsWire | 2025-11-17 09:00:00 |
| World Investment Advisors Takes Position in Labcorp Holdings Inc. $LH | World Investment Advisors purchased a new stake in shares of Labcorp Holdings Inc. (NYSE: LH) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,201 shares of the medical research company's stock, valued at approximately $315,000. A number of | Defense World | 2025-11-05 03:47:05 |
| Labcorp Positioned For Gradual Upside With Resilient Margins And Dividend Support | Laboratory Corp (NYSE: LH) reported third-quarter 2025 adjusted earnings per share of $4.18 on Tuesday, up from $3.50 a year ago, beating the consensus of $4.18. | Benzinga | 2025-10-28 14:45:54 |
| Labcorp Holdings Inc. (LH) Q3 2025 Earnings Call Transcript | Labcorp Holdings Inc. (NYSE:LH ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Christin O'Donnell - Vice President of Investor Relations Adam Schechter - President, CEO & Chairman Julia Wang - CFO & Executive VP Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Michael Cherny - Leerink Partners LLC, Research Division Jack Meehan - Nephron Research LLC Patrick Donnelly - Citigroup Inc., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Joanna Dynak Kevin Caliendo - UBS Investment Bank, Research Division Anna Krasinski Yujin Park - Robert W. | Seeking Alpha | 2025-10-28 12:31:50 |
| LH Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down | Labcorp's Q3 earnings beat forecasts and margins improve, but a trimmed 2025 sales outlook sends shares down. | Zacks Investment Research | 2025-10-28 11:06:11 |
| Here's Why Labcorp Holdings (LH) is a Strong Growth Stock | Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. | Zacks Investment Research | 2025-10-28 10:46:12 |
| Labcorp (LH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates | While the top- and bottom-line numbers for Labcorp (LH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. | Zacks Investment Research | 2025-10-28 10:30:58 |
| Labcorp Holdings (LH) Q3 Earnings Beat Estimates | Labcorp Holdings (LH) came out with quarterly earnings of $4.18 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $3.5 per share a year ago. | Zacks Investment Research | 2025-10-28 09:00:15 |
| Labcorp lifts annual profit forecast on strong diagnostic test demand | Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator benefited from strong demand for its diagnostic tests. | Reuters | 2025-10-28 06:52:09 |
| Labcorp Announces 2025 Third Quarter Results | Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion Diluted EPS: $3.12 versus $2.00 Adjusted EPS: $4.18 versus $3.50 Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timing Adjusted EPS range of $16.15 to $16.50; midpoint raised by $0.05 Free Cash Flow range of $1.17 billion to $1.29 billion; midpoint raised by $25 million Signed several strategic agreements with health systems and regional/local laboratories Advanced business in high-growth specialty testing areas, including oncology and neurology Introduced Labcorp Test Finder and new digital pathology, cytology and microbiology capabilities BURLINGTON, N.C. , Oct. 28, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2025 and updated full-year guidance. | PRNewsWire | 2025-10-28 06:50:00 |
| Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings | Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C. , Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting. | PRNewsWire | 2025-10-23 07:00:00 |
| Labcorp Holdings (LH) Reports Next Week: Wall Street Expects Earnings Growth | Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | Zacks Investment Research | 2025-10-21 11:01:19 |
| Labcorp Holdings Inc. (LH) Hits Fresh High: Is There Still Room to Run? | Labcorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. | Zacks Investment Research | 2025-10-21 10:16:53 |
| LH vs. DHR: Which Stock Is the Better Value Option? | Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now? | Zacks Investment Research | 2025-10-20 12:40:17 |
| Praia Health, Providence, and Labcorp Collaborate to Transform Patient Engagement and Lab Order Adherence | CHICAGO--(BUSINESS WIRE)--A streamlined digital experience improved lab order adherence, reduced no-shows, and enhanced operational efficiency at Providence. | Business Wire | 2025-10-20 09:00:00 |
| Labcorp Gears Up to Report Q3 Earnings: What's in Store for the Stock? | LH is poised for Q3 growth, with revenue and EPS estimates pointing higher as diagnostics and biopharma units deliver strong performances. | Zacks Investment Research | 2025-10-15 09:41:07 |
| Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term | Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. | Zacks Investment Research | 2025-10-14 10:51:12 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2025-12-30 | 2025-12-30 | View Filing |
| 8-K | 2025-12-15 | 2025-12-15 | View Filing |
| 8-K | 2025-12-10 | 2025-12-10 | View Filing |
| 4 | 2025-12-03 | 2025-12-03 | View Filing |
| 3 | 2025-12-03 | 2025-12-03 | View Filing |
| 8-K | 2025-11-24 | 2025-11-24 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-04 | 2025-11-04 | View Filing |
| 4 | 2025-11-04 | 2025-11-04 | View Filing |
| 4 | 2025-11-04 | 2025-11-04 | View Filing |
| 10-Q | 2025-10-31 | 2025-10-31 | View Filing |
| 8-K | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-10-08 | 2025-10-08 | View Filing |
| 8-K | 2025-09-25 | 2025-09-25 | View Filing |
| 8-K | 2025-08-28 | 2025-08-28 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-13 | 2025-08-13 | View Filing |
| 10-Q | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-08-01 | 2025-08-01 | View Filing |
| 4 | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 8-K | 2025-07-24 | 2025-07-24 | View Filing |
| 8-K | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-02 | 2025-07-02 | View Filing |
| 8-K | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-26 | 2025-06-26 | View Filing |
| 4 | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| SD | 2025-05-30 | 2025-05-30 | View Filing |
| S-8 | 2025-05-29 | 2025-05-29 | View Filing |
| S-8 POS | 2025-05-29 | 2025-05-29 | View Filing |
| 8-K | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 10-Q | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| SC 13G/A | 2025-04-24 | 2025-04-24 | View Filing |
| 8-K | 2025-04-10 | 2025-04-10 | View Filing |
| ARS | 2025-04-04 | 2025-04-04 | View Filing |
| DEFA14A | 2025-04-04 | 2025-04-04 | View Filing |
| DEF 14A | 2025-04-04 | 2025-04-04 | View Filing |
| 4 | 2025-04-03 | 2025-04-03 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-31 | 2025-03-31 | View Filing |
| 4 | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-27 | 2025-02-27 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 10-K | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-13 | 2025-02-13 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-02-10 | 2025-02-10 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 26.07% | 1.01 | 421 | 0.03 | 0.12 | 31.53 |
| ADX | 20.78% | 1 | 564 | 0.03 | 0.17 | 26.24 |
| Mean Reversion Strategy | 17.07% | 1 | 209 | 0.02 | 0.07 | 22.53 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |